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Abstract
From September 2014–April 2015, six persons who had occupational exposures to Zaire ebolavirus in
West Africa received investigational agents rVSV-ZEBOV or TKM-100802 for post-exposure
prophylaxis and were monitored in the U.S. All patients experienced self-limited symptoms after PEP;
none developed Ebola virus disease.
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Background
Post-exposure prophylaxis (PEP) after Ebola virus (EBOV) exposure can prevent infection or progression
to severe Ebola virus disease (EVD) when administered promptly in non-human primates [1, 2]. Whether
PEP prevents EVD after EBOV exposure in humans is unknown. Effective PEP is desirable to reduce
progression to EVD after EBOV exposures, especially among healthcare personnel (HCP), who have a
higher EVD incidence than non-HCP [3].
A few individuals were evacuated from West Africa to the U.S. after potential EBOV exposures
and received PEP through FDA-approved emergency Investigation New Drug applications (eIND).
Investigational PEP strategies include a recombinant vesicular stomatitis virus vaccine that expresses a
Zaire ebolavirus surface glycoprotein (rVSV-ZEBOV), a small interfering RNA known as TKM-100802,
favipiravir (RNA polymerase inhibitor), and ZMapp (monoclonal antibody cocktail against EBOV
glycoprotein).
Limited human data exist about PEP use for potential EBOV exposures and symptoms
experienced after PEP administration. Previous reports described rVSV-ZEBOV administration to two
physicians and a laboratory worker with percutaneous EBOV exposures [4-6]. One report of HCP
medically evacuated to the U.K. after potential EBOV exposure described four individuals given PEP
including favipiravir and monoclonal antibody cocktails ZMab, and MIL77 [7]. Of the seven patients
described in these case reports who received investigational PEP, none developed EVD. We describe PEP
use among six persons monitored in the U.S who experienced potential EBOV exposures during 2014–
2015.
Methods
This retrospective case series includes all persons who received PEP after a potential EBOV exposure in
West Africa. Exposures included suspected percutaneous exposure to blood or body fluids of an EVD
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patient, direct contact with an EVD patient while wearing inappropriate or compromised PPE, or other
exposure thought to be of sufficient risk to warrant medical evacuation and consideration of PEP from
September 2014–April 2015. Decisions about medical evacuation, whether to initiate PEP, which
investigational agent would be used for PEP, the duration of hospital monitoring, and clinical and
laboratory monitoring of PEP recipients, were made by clinicians at the treating facilities with input from
public health authorities. The rVSV-ZEBOV vaccine was made available under an eIND application to
the Food and Drug Administration; the protocol specified a dose of 108 pfu. TKM-100802 was also made
available under an eIND application. All patients were monitored initially in U.S. healthcare facilities.
EBOV nucleic acid testing of blood specimens was performed at USAMRIID using the EZ1 Real-time
RT-PCR Assay or at the Centers for Disease Control and Prevention (CDC) using the CDC Ebola Virus
NP and VP40 Real-time RT-PCR Assays. Clinicians who cared for PEP recipients were contacted to
perform chart review using a standardized form to abstract patient characteristics, EBOV exposures, signs
and symptoms after PEP administration, and laboratory results. Data were aggregated and summary
results are presented. Data for one case were published previously [4]. This activity was determined to be
non-research not requiring an Institutional Review Board determination at CDC.
Results
Six persons received PEP for a potential EBOV exposure assessed to be of sufficiently high risk from
September 2014–April 2015. These included three nurses and two physicians who were working in Ebola
treatment units (ETUs) when the exposures occurred, and one non-clinician worker (Table 1). All
potential EBOV exposures were confirmed or suspected percutaneous exposures that occurred in Sierra
Leone; five occurred in ETU patient care areas, and one occurred outside of a nearby ETU (Table 1). Half
(3) of injuries involved hollow-bore needles, and two involved broken medication ampules; one injury
occurred with an unknown sharp object. One person noticed the injury upon doffing personal protective
equipment (PPE); the others recognized the injury immediately. No sharps were known to be
contaminated with EBOV; however, the sharp penetrated potentially contaminated PPE in four PEP
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recipients. One PEP recipient was not wearing any PPE at the time of injury. Percutaneous injuries
occurred while administering medication (3), disposing of sharps (2), and turning a patient with EVD in
bed (1). Upon recognizing the injury, all PEP recipients decontaminated the wound site within 15 minutes
with a chlorine solution. All were medically evacuated to the U.S. within 2–3 days of injury.
Five patients received rVSV-ZEBOV at a dose of 108 pfu in a 1 mL solution; one received
multiple TKM-100802 doses at 0.3–0.5 mg/kg daily. Time from EBOV exposure to PEP initiation was 1–
3 days. Two began PEP while in West Africa; four began PEP on the medical evacuation flight. HIV
post-exposure prophylaxis was given to four individuals; the remaining two declined this intervention.
All PEP recipients were isolated in U.S. healthcare facilities with at least standard, contact and
droplet precautions initially; length of stay ranged from 3–19 days. All reported symptoms that began ≤1
day after PEP initiation (Table 2). Of five who received rVSV-ZEBOV, the most commonly reported side
effects were fever (4), headache (4), and nausea (4). Fever among rVSV-ZEBOV recipients began 12–24
hours after rVSV-ZEBOV administration. Diarrhea was reported among two rVSV-ZEBOV recipients;
diarrhea started 2 days after rVSV-ZEBOV administration for one, and the other had diarrhea that started
one day prior to rVSV-ZEBOV administration. One rVSV-ZEBOV recipient vomited 4 days after PEP
initiation. One rVSV-ZEBOV recipient developed a rash that appeared one day after PEP initiation and
lasted for 18 days. Another rVSV-ZEBOV recipient reported joint pain starting on the day of PEP
initiation and resolving by the next day. Three rVSV-ZEBOV recipients reported pain at the injection site.
The TKM-100802 recipient developed a fever 48 hours after the first dose and developed redness,
swelling, pain, and thrombophlebitis at multiple injection sites. All patients had resolved symptoms upon
hospital discharge and were monitored through 21 days after their potential EBOV exposure.
No patients had laboratory evidence of EBOV infection. The EBOV glycoprotein, which is
expressed by rVSV-ZEBOV, was detected in blood by RT-PCR in four of five rVSV-ZEBOV recipients.
Three rVSV-ZEBOV recipient had detectable IgM and IgG antibodies to EBOV glycoprotein after
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vaccination [4]. EBOV glycoprotein was not detected in blood by RT-PCR for the TKM-100802
recipient. Among rVSV-ZEBOV recipients, EBOV nucleoprotein was not detected in blood collected ≥3
days after exposure by RT-PCR. Three rVSV-ZEBOV recipients had RT-PCR for VSV nucleoprotein
performed on blood; all had VSV detected.
Discussion
We describe six individuals who received PEP after potential EBOV exposures; none had RTPCR evidence of EBOV infection and none developed EVD. All patients reported symptoms after PEP
administration which may have been attributable to PEP or to other factors, such as anxiety, stress, fatigue
related to medical evacuation, or other medications including PEP for HIV.
Safety studies of rVSV-ZEBOV among healthy volunteers have shown that rVSV-ZEBOV is
generally well tolerated; early reactogenicity symptoms are common, and rare occurrences of arthritis and
vesicular dermatitis have been reported [8-10]. While one of the five rVSV-ZEBOV recipients reported
joint pain, none reported arthritis; one person reported a rash. All PEP recipients’ symptoms resolved by
the time of hospital discharge. An ongoing ring vaccination trial, designed to examine use of rVSVZEBOV at a lower dose of 2 x 107 pfu/mL for rapid pre-exposure prophylaxis rather than for PEP [11],
may provide additional data on safety, efficacy in prevention of EVD, and duration of protection [12].
Additional vaccine trials that aim to immunize healthcare and other frontline workers prior to an EBOV
exposure event are ongoing [13].
Of the few reports of TKM-100802 for treatment of EVD, fever and rigors were described in one
patient, the drug was discontinued in another patient due to multi-organ system failure, and a third patient
experienced hypotension after the initial infusion [14, 15]. The patient who received TKM-100802 for
EBOV PEP experienced fever and injection site reactions, and therapy was stopped after dose 5 of 7 due
to these side effects.
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This report is subject to limitations. The small number of PEP recipients makes it difficult to
generalize any of the clinical findings. PEP was uncontrolled; therefore, we cannot determine whether
rVSV-ZEBOV or TKM-100802 were effective in preventing EVD. While the exposures described among
PEP recipients were assumed to be high risk for the purpose of public health monitoring, it was not
determined whether EBOV exposure actually occurred since no testing was performed on the sharps or
PPE to document presence of EBOV.
None of the PEP recipients reported here or previously [4-6] developed evidence of EBOV
infection, but it is unknown whether PEP prevented EVD. While the effectiveness of PEP remains unclear
from this small case series, high-risk exposures are likely to occur in the future, and timely PEP
availability and administration may help in reducing the risk of progression to EVD. Priorities for PEP
research include using observational studies or clinical trials when feasible to determine the highest risk
EBOV exposures, the optimal time and “window period” for PEP, the safety profile of candidate PEP
therapies, and the most effective interventions to prevent EVD after high-risk EBOV exposures.

Notes
Acknowledgments: We thank Bobbie Rae Erickson, MPH, and Amy Schuh, PhD, of the Centers for
Disease Control and Prevention (CDC) for assistance with real-time reverse transcription–polymerase
chain reaction; the healthcare teams at the Emory Serious Communicable Diseases Unit, the Nebraska
Biocontainment Unit, and the National Institutes of Health for the care of these patients; John Beigel
(National Institute of Allergy and Infectious Diseases) for facilitating access to PEP for selected patients;
Oliver Morgan and Jane Seward (CDC) for their roles in facilitating coordination of those involved in the
care of selected patients; and Tekmira, the Public Health Agency of Canada, and New Link Genetics for
providing the investigational agents.

8
Funding: This work was supported by the United States Centers for Disease Control and Prevention. The
care of patients at the Emory Serious Communicable Diseases Unit was supported in part by the National
Center for Advancing Translational Sciences of the National Institutes of Health (award UL1TR000454).
The care of patients at the NIH Clinical Center was funded by the National Institute of Allergy and
Infectious Diseases.

Disclaimer: The views expressed are those of the authors, and do not necessarily represent the official
position of the Centers for Disease Control and Prevention.

Disclosures. Dr. Ströher reports In addition, Dr. Ströher has a patent Recombinant vesicular stomatitis
virus vaccines for viral hemorrhagic fevers licensed to NewLink Genetics; Merck & Co., Inc. All other
authors have no reported conflicts of interest.

9

References
1.

Marzi A, Robertson SJ, Haddock E, et al. Ebola Vaccine. VSV-EBOV rapidly protects macaques
against infection with the 2014/15 Ebola virus outbreak strain. Science 2015; 349(6249): 739-42.

2.

Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against
a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010;
375(9729): 1896-905.

3.

Kilmarx PH, Clarke KR, Dietz PM, et al. Ebola virus disease in health care workers--Sierra Leone,
2014. MMWR Morbidity And Mortality Weekly Report 2014; 63(49): 1168-71.

4.

Lai L, Davey R, Beck A, et al. Emergency postexposure vaccination with vesicular stomatitis virusvectored Ebola vaccine after needlestick. JAMA 2015; 313(12): 1249-55.

5.

Cnops L, Gerard M, Vandenberg O, et al. Risk of Misinterpretation of Ebola Virus PCR Results
After rVSV ZEBOV-GP Vaccination. Clinical Infectious Diseases 2015; 60(11): 1725-6.

6.

Gunther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus
in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011; 204 Suppl 3: S785-90.

7.

Jacobs M, Aarons E, Bhagani S, et al. Post-exposure prophylaxis against Ebola virus disease with
experimental antiviral agents: a case-series of health-care workers. The Lancet Infectious
Diseases 2015.

8.

Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and
Europe - Preliminary Report. The New England Journal Of Medicine 2015.

9.

Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the
VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
The Lancet Infectious Diseases 2015.

10
10.

Regules JA, Beigel JH, Paolino KM, et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
- Preliminary Report. The New England Journal Of Medicine 2015.

11.

Ebola ca suffit ring vaccination trial c. The ring vaccination trial: a novel cluster randomised
controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with
special reference to Ebola. BMJ 2015; 351: h3740.

12.

Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored
vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination
cluster-randomised trial. Lancet 2015; 386(9996): 857-66.

13.

World Health Organization. Ebola vaccines, therapies, and diagnostics. Available at:
http://www.who.int/medicines/emp_ebola_q_as/en/. Accessed November 10, 2015.

14.

Kraft CS, Hewlett AL, Koepsell S, et al. The Use of TKM-100802 and Convalescent Plasma in 2
Patients With Ebola Virus Disease in the United States. Clinical Infectious Diseases 2015; 61(4):
496-502.

15.

Liddell AM, Davey RT, Jr., Mehta AK, et al. Characteristics and Clinical Management of a Cluster
of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the
United States. Annals Of Internal Medicine 2015; 163(2): 81-90.

11

Table 1: Potential high-risk EBOV exposures experienced by U.S. PEP recipients
Occupation

Exposure

PEP (time from EBOV
exposure to initiation)

Physician

Physician manipulated an intravenous cannula on a viremic EVD

TKM-100802 (2 days)

patient; while wearing the same gloves, physician drew up medication
from an ampule and accidentally stuck needle through both pairs of
gloves.
Nurse

Nurse was providing patient care in an ETU, which included delivering

rVSV-ZEBOV (3 days)

medications and meals and cleaning up bloody emesis and broken glass
medication ampules. The nurse did not recognize that an injury had
occurred, but during doffing noted a tear in one glove and found a
bleeding laceration.
Other ETU

Worker picked up with bare hands a cardboard box that contained

worker

sharps lying in the grass near an ETU that was being renovated.
Hollow-bore needle pierced ungloved hand. Unknown whether needle
could have been contaminated with EBOV; ETU had not had an EVD

rVSV-ZEBOV (24 hours)
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patient for about 2 weeks.
Nurse

Nurse broke a glass medication ampule while working in an ETU. The

rVSV-ZEBOV (27 hours)

nurse continued to work for about 15 minutes before inspecting gloves;
both layers of gloves had been penetrated and blood was noted at the
point of penetration.
Physician

A hollow-bore needle that was not contaminated with body fluids from

rVSV-ZEBOV (43 hours)

an EVD patient pierced contaminated gloves while physician was
disposing of needle in an overflowing sharps container.
Nurse

Nurse felt sharp prick to finger while turning a severely ill EVD patient

rVSV-ZEBOV (3 days)

with an open draining wound; no needle/sharp found. No skin puncture
noted initially, but red pin-sized wound found on finger next day.
Abbreviations: EBOV, Ebola virus. PEP, post-exposure prophylaxis. EVD, Ebola virus disease. TKM-100802. rVSV-ZEBOV. ETU, Ebola
treatment unit.
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Table 2: Characteristics, signs, and symptoms of persons receiving post-exposure prophylaxis for
potential high-risk EBOV exposures (N=6)
Characteristic
Male, n (%)

4 (67)

Age, median years (range)

39 (36–45)

Occupational role at time of exposure, n (%)
Nurse

3 (50)

Physician

2 (33)

Non-healthcare worker

1 (17)

Exposed by percutaneous injury, n (%)

6 (100)

Type of sharp, n (%)
Hollow-bore needle

3 (50)

Broken medication ampule

2 (33)

Unknown

1 (17)

Sharp and PPE (glove) EBOV contamination status, n (%)
Non-contaminated sharp through contaminated PPE

2 (33)

Non-contaminated sharp through PPE recently cleaned with chlorine
solution

1 (17)

Unknown sharp through contaminated PPE

2 (33)

Unknown sharp, no PPE

1 (17)

Activity at time of sharps injury, n (%)
Medication administration

3 (50)

Disposing of sharps

2 (33)

Turning patient

1 (17)

Time from exposure to initial decontamination, range

5-15 minutes
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Type of PEP received, n (%)
rVSV-ZEBOV

5 (83)

TKM-100802

1 (17)

Time from exposure to PEP initiation, range

1–3 days

Location of PEP initiation, n (%)
West Africa

2 (33)

On medical evacuation flight

4 (67)

Time from PEP administration to first sign/symptom, range

10 hours – 2 days
TKMrVSV-ZEBOV

100802

(n=5)

(n=1)

4

Yes

37.3–39.1

38.1

Myalgias

3

Unknown

Chills/rigors

3

No

Diaphoresis

3

No

Hypotension

1

Yes*

Malaise

2

No

Fatigue

3

Unknown

Headache

4

Yes

Dizziness

1

No

Arthralgia

1

No

Arthritis

0

No

Rash

1

No

Chest pain

1

No

Systemic reactions
Fever
Highest fever, range °C
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Dyspnea

1

No

Hypoxia

1

No

Nausea

4

No

Vomiting

1

No

Diarrhea

2

No

Redness

0

Yes

Swelling

0

Yes

Pain

3

Yes

Thrombophlebitis

0

Yes

Local reactions

* Lowest blood pressure was 90/56 while asleep; resolved without intervention.
Abbreviations: EBOV, Ebola virus. PPE, personal protective equipment. PEP, post-exposure prophylaxis.
rVSV-ZEBOV. TKM-100802.

